Inhibitor Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
INTIStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
| Item 15. | Exhibits, Financial Statement Schedules. |
|---|
The following exhibits are filed with this Report.
| Exhibit No. | Description |
| 3.1 | Certificate of Incorporation of the Company, dated July 30, 2013 as filed on 8-K on August 16, 2013 |
| 3.2 | Certificate of Amendment to the Company’s Certificate of Incorporation, dated May 19, 2016, as filed with Form 8-K, dated May 26, 2016 |
| 3.3 | Certificate of Amendment to the Company’s Certificate of Incorporation, dated July 13, 2015, as filed with Form S-1/A on July 22, 2015 |
| 3.4 | Second Amended and Restated Bylaws of the Company, adopted July 12, 2023, as filed with Form 8-K, dated August 29, 2023 |
| 3.5 | Amended and Restated Certificate of Designation of Series B Preferred Stock of the Company, dated February 1, 2019, filed with Definitive Information Statement, filed on January 8, 2019 |
| 3.6 | Certificate of Amendment to the Company’s Certificate of Incorporation, dated August 20, 2019, as filed with Form 8-K dated August 20, 2019 |
| 3.7 | Charter of the Scientific Advisory Board, dated October 13, 2023, filed with Form 8-K dated October 13, 2023 |
| 4.1 | Warrant, dated June 24, 2014 issued to Hedgepath, LLC, as filed with Form 8-K, dated June 30, 2014 |
| 10.1+ | Master Clinical Services Agreement, dated June 15, 2015, by and between the Company and SciQuus, Inc., as filed with Form 10-Q on August 14, 2015 |
| 10.2 | Stipulation and Agreement of Compromise, Settlement, and Release, dated September 9, 2022, as filed with Form 8-K, dated December 19, 2022 |
| 10.3 | License Agreement by and between the Company and Mayne Pharma, dated December 13, 2022, as filed with Form 8-K, dated December 19, 2022 |
| 10.4 | Employment Agreement by and between the Company and Francis E. O’Donnell, dated December 13, 2022, as filed with Form 8-K, dated December 19, 2022 |
| 10.5 | Employment Agreement by and between the Company and James A. McNulty, dated December 13, 2022, as filed with Form 8-K, dated December 19, 2022 |
| 10.6 | License Agreement by and between the Company and Johns Hopkins University, Dated December 12, 2023 (Portions of this exhibit have been redacted pursuant to a request for confidential treatment.), as filed with Form 10-K, dated March 29, 2024 |
| 23.1* | Consent of Cherry Bekaert LLP |
| 31.1* | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2* | Certification of the Interim Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1*# | Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2*# | Certification of the Interim Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.ins | Inline XBRL Instance Document |
| 101.sch | Inline XBRL Taxonomy Extension Schema Document |
| 101.cal | Inline XBRL Taxonomy Calculation Linkbase Document |
| 101.def | Inline XBRL Taxonomy Definition Linkbase Document |
| 101.lab | Inline XBRL Taxonomy Label Linkbase Document |
| 101.pre | Inline XRL Taxonomy Presentation Linkbase Document |
| * | Filed herewith |
| + | Confidential treatment has been granted for certain portions of this exhibit pursuant to 17 C.F.R. Sections 200.8(b)(4) and 240.24b-2. |
| # | A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.